Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion

Acta Ophthalmologica Scandinavica

Volumn 77, Issue 6, 1999, Pages 622-624

  Kalayci, Defne ^a,b   Gürgey, Aytemiz ^a   Güven, Dilek ^a   Parlak, Hülya ^a   Hasiripi, Hikmet ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Factor V Leiden; Prothrombin 20210 A

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0342751303     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.1999.770602.x     Document Type: Article

References (21)

1. Appiah AP & Trempe CL (1989): Differences in contributory factors among hemicentral, central, and branch retinal vein occlusions. Ophthalmology 96: 364-366.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA & Reitsma PH (1994): Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64-67.
3. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH & Hay CRM (1997): The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 98: 353-355.
4. Dahlbäck B (1995): Inherited thrombophilia: Resistance to activated protein C as a pathogenetic factor of venous thromboembolism. Blood 85: 607-614.
5. Dahlbäck B (1994): Physiological Anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 94: 923-927.
6. Demirci YK, Yavuz S, Özbek U, Akarçay K, Kir N, Atamer T & Öngör E (1997): Retinal ven tikanikhǧi geçiren genç erişkinlerde aktive protein C direncinin araştirilmasi. XXXI. Turkish National Ophthalmology Congress, Abstract Book p135.
7. Gottlieb JL, Blice JP, Mestichelli B, Konkle BA & Benson WE (1998): Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 116: 577-579.
8. Gürgey A, Mesci L, Renda Y, Olcay L, Koçak N & Erdem G (1996): Factor V Q 506 mutation in children with thrombosis. Am J Hematol 53: 37-39.
9. Gürgey A, Hiçsönmez G, Parlak H, Balta G & Çeliker A (1998): The prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. Am J Hematol 59: 179-180.
10. Gürgey A & Mesci L (1997): The prevalence of factor V Leiden (1691 G A) mutation in Turkey. Turk J Pediatr 39: 313-315.
11. Hodgkins PR, Perry DJ, Sawcer SJ & Keast-Butler J (1995): Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Eye 9: 760-762.
12. Larsson J, Olafsdottir E & Bauer B (1996): Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 80: 200-202.
13. Larsson J, Sellman A & Bauer B (1997): Activated protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol 81: 832-834.
14. Linna T, Ylikorkala A, Kontula K, Puska P & Tervo T (1997): Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 77: 212-24,
15. Poort SR, Rosendaal FR, Reitsma PH & Bertina RM (1996): A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88: 3698-703.
16. Rees D, Cox M & Clegg J (1995): World distribution of factor V Leiden. Lancet 346: 1133-1134.
17. Rosendaal FR, Koster T, Vandenbroucke JP & Reitsma PH (1995): High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85: 1504-1508.
18. Swensson PJ & Dahlbäck B (1994): Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330: 517-521.
19. Vine AK & Samama MM (1997): Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion. Am J Ophthalmol 124: 673-676.
20. Williamson TH, Rurnley A & Lowe GDO (1996): Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 80: 203-208.
21. Zöller B, Svenson PJ, He X & Dahlbäck B (1994): Identification of the same factor V gene mutation in 47 out of 50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest 94: 2521-2524.